Kura Oncology Corp (KURA): Forward Price-to-Revenue Multiple

Corporate company logo of Kura (KURA)

Kura Oncology, Inc. (KURA) collaborates with biopharma behemoths and research centers to develop advanced therapies. The company minimizes operational risks by adapting a single molecule to target various blood cancer mutations. A narrow precision oncology profile is supported by solid capital, while the forward P/S valuation reflects market expectations, with the metric holding around 8.60.

KURA kuraoncology.com: Forward Price to Sales in the range 02/28/2025 - 11/18/2026

Comprehensive metric breakdowns and analytics for kuraoncology.com (KURA)

- market price and analyst price targets:
- stock exchange capitalization data:
Initial company analysis:KURA (Kura Oncology, Inc.)
Manufactured products of Kura Oncology, Inc.

For Kura Oncology, Inc. (KURA), valuation is based on expectations regarding drug commercialization. The forward price-to-sales ratio reflects the market value of one dollar of projected revenue, allowing for an assessment of the premium paid for future growth. This chart captures changes in analyst consensus forecasts. The current multiple depends directly on the outcomes of ziftomenib trials, where any success sharply reduces the risk of the asset being undervalued.